Vancomycin 265/309 (85.8%) 76/265 (25.3%) 198/309 (64.1%) † Clinical cure is resolution of diarrhea following the recommended dose of drug (fidaxomicin: 200 mg twice a day; vancomycin ...

None of these patients had a rise in the platelet count until the vancomycin was discontinued and an alternative antibiotic started. The vancomycin was stopped early in the remaining 14 patients ...

Antibiotics such as vancomycin require careful monitoring and dosing regimens that take into account patient-specific factors impacted by the drug’s pharmacokinetics and pharmacodynamics ...

The antibiotic vancomycin, recommended as first-line treatment for infection caused by the deadly superbug C. difficile (C.

The peptide material was tested in bacterial cultures, in combination with two different antibiotics: oxacillin and vancomycin. The bacteria included in the experiments were two types of ...

Vancomycin (as HCl) 500mg/vial, 1g/vial; lyophilized pwd for IV infusion after reconstitution and dilution. The bactericidal action of vancomycin results primarily from inhibition of cell-wall ...

V-161, a novel compound targeting the Na+ -V-ATPase enzyme in vancomycin-resistant Enterococcus faecium (VRE), significantly reduces bacterial growth and colonization.

If a drug-resistant phenotype were to evolve and ... health care workers reported the first cases of vancomycin-resistant MRSA. In other words, even "last-resort" vancomycin doesn't always work.

Acute kidney injury (AKI) is a significant concern in patients receiving certain antibiotics, particularly vancomycin and piperacillin-tazobactam. These medications are commonly used to treat ...

The major objective of this research collaboration is to develop new therapeutic drug candidates which target antimicrobial resistant pathogens. This work will utilize the Immuron technology platform, ...

The growth of the vancomycin market is driven by several key factors, including the increasing prevalence of antibiotic-resistant infections, advancements in pharmaceutical manufacturing ...